Income statement
USD
Annual
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 424M | 403M | 404M | 0 |
| Gross Profit | 238M | 235M | 230M | 0 |
| Operating Income | 72M | 10M | -15M | 0 |
| EBITDA | 105M | 90M | 7M | 500K |
| Net Income | 40M | 36M | -107M | 500K |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$0.0251
+0.00% today
1Y Change
-98.28%
Window
Jun 23, 2025 → Jun 10, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 10, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Procaps Group S.A. (PROCF) is a Healthcare stock with a market cap of $100.00M and listed on PNK. The stock last traded around $0.03 and down 98.3% across the available one-year price window (Jun 23, 2025 → Jun 10, 2026). Baseline metrics include revenue growth of +5.1%, EPS growth of +11.1%, a dividend yield of 0.0%. What stands out right now is revenue +5.1%, EPS +11.1%, free cash flow +503.0% with operating margin 12.8% and ROIC 12.1%. Valuation is more restrained than many high-expectation growth names at P/E 2.4 and price/sales 0.2. Stock Foundry combines PROCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PROCF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PROCF Max Drawdown
-99.98%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PROCF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
$500.5K
+100.5% YoY
Free Cash Flow
-$774.8K
-108.1% YoY
Revenue Growth
+5.1%
EPS Growth
+11.1%
Gross Margin
58.4%
Net Margin
10.4%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 424M | 403M | 404M | 0 |
| Gross Profit | 238M | 235M | 230M | 0 |
| Operating Income | 72M | 10M | -15M | 0 |
| EBITDA | 105M | 90M | 7M | 500K |
| Net Income | 40M | 36M | -107M | 500K |
| EPS (Diluted) | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Cash & Equivalents | 18M | 43M | 72M | 956K |
| Total Assets | 472M | 443M | 450M | 202M |
| Total Liabilities | 473M | 480M | 520M | 145K |
| Shareholder Equity | 210K | -36M | -69M | 202M |
| Total Debt | 300M | 287M | 253M | 0 |
| Net Debt | 282M | 244M | 181M | -956K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
775K
-102.2% YoY
Capital Expenditures
3
+100.0% YoY
Free Cash Flow
775K
-108.1% YoY
Key ratios
Gross Margin
58.4%
Operating Margin
12.8%
Net Margin
10.4%
ROE
-221.9%
Debt / Equity
-303.86x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.